HIV

The behavioral economic biases of 43 African American young adults aged 18 to 24 were evaluated on 4 fronts: present bias, information salience, overoptimism, and loss aversion.

Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mt. Sinai, talks about what factors can contribute to medication nonadherence in people with HIV, and the different levels of support that might be available to patients.

In a cohort of patients in New York with mpox, HIV status did not seem to affect treatment outcomes with tecovirimat, although more research is needed.

A recent study found that HIV is 2.5 times more common in people who use mental health services compared with the general population in South London.

Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mount Sinai, discusses how neurologic symptoms in individuals with HIV can present in various places in the body while also possibly pointing to a neurologic condition.

In the first 2 years after receiving an HIV diagnosis, people with HIV were about 3 times more likely to develop depression, use antidepressants, and undergo electroconvulsive therapy—and 10 times more likely to commit suicide—compared with people without HIV.

HIV infection was more common among those who died of mpox compared with survivors, with an HIV prevalence of 93.9% and 38.3%, respectively, based on available information.

According to interim results from the REPRIEVE study, individuals with HIV who took the daily statin experienced a 35% reduced risk of major adverse cardiovascular (CVD) events, compared with those who received a placebo.

A test using a single spot of dried blood successfully detected HIV, hepatitis B, and hepatitis C in all 60 samples with known amounts of each virus.

Participants with HIV who inject drugs were more likely to initiate antiretroviral therapy and utilize substance use care after participating in group stigma-coping sessions, compared with those who received usual services.

Research showed that HIV incidence and mortality rates were highest among transgender women who were Black or Latinx or lived in the southern United States.

The ruling does not completely get rid of all preventive services coverage under the Affordable Care Act; it only applies to updates or new recommendations made by the US Preventative Services Task Force since March 2010.

The ruling of Braidwood Management v Becerra puts HIV pre-exposure prophylaxis (PrEP) coverage at risk, potentially leading to more than 2000 preventable HIV infections in the coming year.

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

Similar to findings among young adults, children with HIV in Tanzania were found to have lower distortion product otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABR) wave V amplitudes, compared with children without HIV.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.

Dr Sension underlines the value of CD4 recovery from payer and clinician perspectives.

Study results indicates that the injectable antiretroviral therapy can benefit patients who are historically underserved and may face treatment barriers, including those with mental illness.

Since 2004, the number of individuals with HIV receiving antiretroviral therapy (ART) has increased 300-fold through the US President’s Emergency Plan for AIDS Relief (PEPFAR).

Key opinion leaders highlight barriers to MDR HIV treatment adherence.

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

Body mass index and nadir CD4 count were major factors in SARS-CoV-2 humoral immune repertoire among people with HIV.